Telithromycin activity is reduced by efflux in Streptococcus pyogenes
Open Access
- 1 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (4) , 489-495
- https://doi.org/10.1093/jac/dki033
Abstract
Objectives: To investigate whether telithromycin is a substrate for efflux pumps in Streptococcus pyogenes. Methods: The distribution of telithromycin MICs was analysed for two distinct collections of Italian (n=486) and Spanish (n=210) S. pyogenes strains. The effect of an efflux mechanism was investigated using [3H]telithromycin. Results: Telithromycin MIC ranges were ≤ 0.004–0.06 mg/L (MIC50 and MIC90, 0.01 mg/L) in erythromycin-susceptible strains (lacking both mef and erm genes) and 0.01–1 mg/L (MIC50 and MIC90, 0.5 mg/L) in strains endowed with the M phenotype and expressing the mef(A) gene. A distinct telithromycin efflux was detected in the strains expressing the mef(A) gene, but not in those expressing the erm(B) gene, nor in the susceptible strains lacking mef(A) or erm genes. Efflux reversibility by addition of an inhibiting compound (sodium arsenate) was demonstrated. An msr-like sequence was also found in all strains effluxing telithromycin, but not in the others. Conclusions: This study shows that telithromycin can be removed from S. pyogenes by efflux. That the efflux is related to the presence of the mef(A) gene is demonstrated, but—owing to the increasingly evident complexity of S. pyogenes efflux systems—the possibility that other genes may contribute to the efflux cannot be excluded.Keywords
This publication has 31 references indexed in Scilit:
- Impact of Ketolides on Resistance Selection and Ecologic Effects during Treatment for Respiratory Tract InfectionsMicrobial Drug Resistance, 2004
- Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycinJournal of Antimicrobial Chemotherapy, 2003
- Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000Journal of Antimicrobial Chemotherapy, 2002
- Pharmacoepidemiological Analysis of Provincial Differences between Consumption of Macrolides and Rates of Erythromycin Resistance among Streptococcus pyogenes Isolates in SpainJournal of Clinical Microbiology, 2002
- Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutationsJournal of Antimicrobial Chemotherapy, 2002
- Emergence of Group A Streptococcus Strains with Different Mechanisms of Macrolide ResistanceAntimicrobial Agents and Chemotherapy, 2002
- Surveillance of resistance in bacteria causing community‐acquired respiratory tract infectionsClinical Microbiology & Infection, 2002
- Ketolides—telithromycin, an example of a new class of antibacterial agentsClinical Microbiology & Infection, 2000
- Streptococcus pyogenes Erythromycin Resistance in ItalyEmerging Infectious Diseases, 1999
- Molecular cloning and functional analysis of a novel macrolide‐resistance determinant, mefA, from Streptococcus pyogenesMolecular Microbiology, 1996